Federal Register / Vol. 65, No. 100 / Tuesday, May 23, 2000 / Notices 33355

Drug Schedule

Glutethimide (2550) ........................... II

Nabilone (7379) ................................. II

1-Phenylcyclohexylamine (7460) ...... II

Phencyclidine (7471) ......................... II

1-Piperid-inocyclohexanecarbonitrile

(8603).

II

Alphaprodine (9010) .......................... II

Cocaine (9041) .................................. II

Codeine (9050) ................................. II

Dihydrocodeine (9120) ...................... II

Oxycodone (9143) ............................. II

Hydromorphone (9150) ..................... II

Diphenoxylate (9170) ........................ II

Benzoylecgonine (9180) ................... II

Ethylmorphine (9190) ........................ II

Hydrocodone (9193) ......................... II

Levomethorphan (9210) .................... II

Levorphanol (9220) ........................... II

Isomethadone (9226) ........................ II

Meperidine (9230) ............................. II

Methadone (9250) ............................. II

Methadone-intermediate (9254) ........ II

Morphine (9300) ................................ II

Levo-alphacetylmethadol (9648) ....... II

Oxymorphone (9652) ........................ II

Alfentanil (9737) ................................ II

Sufentanil (9740) ............................... II

Fentanyl (9801) ................................. II

The firm plans to manufacture small

quantities of the listed controlled

substances to make deuterated and

nondeuterated drug reference standards

which will be distributed to analytical

and forensic laboratories for drug testing

programs.

Any other such applicant and any

person who is presently registered with

DEA to manufacture such substances

may file comments or objections to the

issuance of the proposed registration.

Any such comments or objections

may be addressed, in quintuplicate, to

the Deputy Assistant Administrator,

Office of Diversion Control, Drug

Enforcement Administration, United

States Department of Justice,

Washington, D.C. 20537, Attention: DEA

Federal Register Representative (CCR),

and must be filed no later than July 24,

2000.

Dated: May 11, 2000.

John H. King,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 00–12844 Filed 5–22–00; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importation of Controlled Substances;

Notice of Application

Pursuant to Section 1008 of the

Controlled Substances Import and

Export Act (21 U.S.C. 958(i)), the

Attorney General shall, prior to issuing

a registration under this Section to a

bulk manufacturer of a controlled

substance in Schedule I or II and prior

to issuing a regulation under Section

1002(a) authorizing the importation of

such a substance, provide

manufacturers holding registrations for

the bulk manufacture of the substance

an opportunity for a hearing.

Therefore, in accordance with Section

1301.34 of Title 21, Code of Federal

Regulations (CFR), notice is hereby

given that on January 10, 2000, Sigma

Chemical Company, Subsidiary of

Sigma-Aldrich Company, 3500 Dekalb

Street, St. Louis, Missouri 63118, made

application to the Drug Enforcement

Administration to be registered as an

importer of the basic classes of

controlled substances listed below:

Drug Schedule

Cathinone (1235) .............................. I

Methcathinone (1237) ....................... I

Aminorex (1585) ................................ I

Methaqualone (2565) ........................ I

Ibogaine (7260) ................................. I

Lysergic acid diethylamide (7315) .... I

Marihuana (7360) .............................. I

Tetrahydrocannabinols (7370) .......... I

Mescaline (7381) ............................... I

4-Bromo-2, 5-

dimethoxyamphetamine (7391).

I

4-Bromo-2, 5-

dimethoxyphenethylamine (7392).

I

2, 5-Dimethoxyamphetamine (7396) I

3, 4-Methylenedioxyamphetamine

(7400).

I

N-Hydroxy-3, 4-

methylenedioxyamphetamine

(7402).

I

3, 4-Methylenedioxy-Nethylamphetamine (7404).I

3, 4-

Methylenedioxymethamphetamine

(7405).

I

4-Methoxyamphetamine (7411) ........ I

Bufotenine (7433) .............................. I

Psilocyn (7438) ................................. I

Heroin (9200) .................................... I

Normorphine (9313) .......................... I

Etonitazene (9624) ............................ I

Amphetamine (1100) ......................... II

Methamphetamine (1105) ................. II

Methylphenidate (1724) .................... II

Amobarbital (2125) ............................ II

Pentobarbital (2270).

Secobarbital (2315 ............................ II

Glutethimide (2550) ........................... II

Phencyclidine (7471) ......................... II

Cocaine (9041) .................................. II

Codeine (9050) ................................. II

Diprenorphine (9058) ........................ II

Oxycodone (9143) ............................. II

Hydromorphone (9150) ..................... II

Benzoylecgonine (9180) ................... II

Ethylmorphine (9190) ........................ II

Hydrocodone (9193) ......................... II

Levorphanol (9220) ........................... II

Meperidine (9230) ............................. II

Drug Schedule

Methadone (9250) ............................. II

Dextropropoxyphene, bulk (non-dosage forms) (9273).II

Morphine (9300) ................................ II

Thebaine (9333) ................................ II

Opium powdered (9639) ................... II

Oxymorphone (9652) ........................ II

Fentanyl (9801) ................................. II

The firm plans to repackage and offer

as pure standards controlled substances

in small milligram quantities for drug

testing and analysis.

Any manufacturer holding, or

applying for, registration as a bulk

manufacturer of these basic classes of

controlled substances may file written

comments on or objections to the

application described above and may, at

the same time, file a written request for

a hearing on such application in

accordance with 21 CFR 1301.43 in

such form as prescribed by 21 CFR

1316.47.

Any such comments, objections, or

requests for a hearing may be addressed,

in quintuplicate, to the Deputy Assistant

Administrator, Office of Diversion

Control, Drug Enforcement

Administration, United States

Department of Justice, Washington, D.C.

20537, Attention: DEA Federal Register

Representative (CCR), and must be filed

no later than June 22, 2000.

This procedure is to be conducted

simultaneously with and independent

of the procedures described in 21 CFR

1301.34(b), (c), (d), (e), and (f). As noted

in a previous notice at 40 FR 43745–46

(September 23, 1975), all applicants for

registration to import basic class of any

controlled substance in Schedule I or II

are and will continue to be required to

demonstrate to the Deputy Assistant

Administrator, Office of Diversion

Control, Drug Enforcement

Administration that the requirements

for such registration pursuant to 21

U.S.C. 958(a), 21 U.S.C. 823(a), and 21

CFR 1311.42(a), (b), (c), (d), (e), and (f)

are satisfied.

Dated: April 25, 2000.

John H. King,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 00–12843 Filed 5–22–00; 8:45 am]

BILLING CODE 4410–09–M